AnaptysBio Up Slightly In IPO

San Diego-based AnaptysBio, which develops antibodies for treating inflammation, has raised $75.0M in its IPO, and closed up slightly in its first day of trading on Thursday. Anaptys priced its IPO on Wednesday night at $15.00 per share, at the midpoint of its $14.00 to $16.00 estimated IPO range, and closed the day at $17.00 per share. AnaptysBio is backed by Frazier Healthcare, Novo A/S, Avalon Ventures, Alloy Ventures, Biotechnology Value Fund, HBM Healthcare Investments, and others. The company now trades as ANAB on the NASDAQ Global Select Market.